Research Article
Network of Mediators for Vascular Inflammation and Leakage Is Dysbalanced during Cytoreductive Surgery for Late-Stage Ovarian Cancer
Table 1
Patient and procedural details.
| | Parameter | Median (25th and 75th percentiles) |
| | Patient details | | 26 | | Age (years) | 70 (57-75) | | Body mass index (kg/m2) | 27.3 (22.5-30.6) | | FIGO stage III ( (%)) | 19 (73) | | FIGO stage IV ( (%)) | 7 (27) | | Neoadjuvant oncostatic chemotherapy ( (%)) | 10 (38) | | Procedural details | | Duration of surgery (min) | 456 (323-542) | | Duration of anesthesia (min) | 618 (506-689) | | Duration of mechanical ventilation (min) | 1115 (755-1459) | | Fluid intake (ml/kghr) | 13.1 (10.6-15.4) | | Fluid balance (ml/kghr) | 9.4 (7.9-12.6) | | Estimated blood loss (ml/hr) | 76.1 (41.2-140) | | Patients with packed red blood cell (PRBC) transfusion ( (%)) | 15 (58) | | Numbers of PRBC units transfused | 2 (0-4) | | Urine output (ml/kghr) | 1.6 (1.1-2.2) | | Max. norepinephrine dosage (μg/kgmin) | 0.07 (0.06-0.15) | | Max. dobutamine dosage (μg/kgmin) | 0 (0-0.28) | | Max. serum lactate intraop. (mmol/l) | 1.61 (1.18-1.87) | | Hyperthermic intraperitoneal chemotherapy (HIPEC) ( (%)) | 6 (23) | | Length of stay in hospital (days) | 25 (14-34) | | Intrahospital mortality (%) | 0 | | 3-month mortality (%) | 0 |
|
|
